BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.

BBOT | NDAQ

Overview

Corporate Details

ISIN(s):: KYG4444H1011
LEI:
Country:: United States of America
Address:: 256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO
Website:: https://bbotx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics for precision oncology. The company leverages an expert understanding of RAS signaling biology to inform rational drug design, with a focus on treating RAS-dependent cancers. Its approach aims to maximize target inhibition by developing therapies that can inhibit a broad spectrum of KRAS mutants in both their active (ON) and inactive (OFF) states, as well as target RAS-driven PI3K activation. The company's mission is to translate this scientific knowledge into transformative medicines for patients with cancers that have clear genetic drivers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Biosergen AB Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.	Sweden	BIOSGN
Bio Solution Co.,Ltd. Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.	South Korea	086820
Biosynex European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.	France	ALBIO
BIO-TECHNE Corp Develops reagents and instruments for life sciences research and clinical diagnostic markets.	United States of America	TECH
biote Corp. Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.	United States of America	BTMD
Biotest AG Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.	Germany	BIO3
Biotika A.S. Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.	Slovakia	BSL
Bioton S.A. Develops and manufactures recombinant human insulin for global diabetes care solutions.	Poland	BIO
BIOVENTIX PLC Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.	United Kingdom	BVXP
Bioversys N Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.	Switzerland	BIOV